Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes

References

1. 1.↵
   1. Brat DJ,
   2. Verhaak RG,
   3. Aldape KD, et al

   ; Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015;372:2481–98 doi:10.1056/NEJMoa1402121 pmid:26061751

   CrossRefPubMed
2. 2.↵
   1. Eckel-Passow JE,
   2. Lachance DH,
   3. Molinaro AM, et al

   . Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015;372:2499–2508 doi:10.1056/NEJMoa1407279 pmid:26061753

   CrossRefPubMed
3. 3.↵
   1. Louis DN,
   2. Perry A,
   3. Reifenberger G, et al

   . The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803–20 doi:10.1007/s00401-016-1545-1 pmid:27157931

   CrossRefPubMed
4. 4.↵
   1. Yan H,
   2. Parsons DW,
   3. Jin G, et al

   . IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–73 doi:10.1056/NEJMoa0808710 pmid:19228619

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Chamberlain MC,
   2. Born D

   . Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors. J Neurooncol 2015;125:249–51 doi:10.1007/s11060-015-1906-y pmid:26341371

   CrossRefPubMed
6. 6.↵
   1. Aldape K,
   2. Burger PC,
   3. Perry A

   . Clincopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 2007;131:242–51 pmid:17284109

   PubMedWeb of Science
7. 7.↵
   1. Liu X,
   2. Gerges N,
   3. Korshunov A, et al

   . Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012;124:615–25 doi:10.1007/s00401-012-1031-3 pmid:22886134

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Kannan K,
   2. Inagaki A,
   3. Silber J, et al

   . Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 2012;3:1194–1203 doi:10.18632/oncotarget.689 pmid:23104868

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Reuss DE,
   2. Kratz A,
   3. Sahm F, et al

   . Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 2015;130:407–17 doi:10.1007/s00401-015-1454–58 pmid:26087904

   CrossRefPubMed
10. 10.↵
    1. Gleize V,
    2. Alentorn A,
    3. Connen de Kérillis L, et al

    ; POLA network. CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas. Ann Neurol 2015;78:355–74 doi:10.1002/ana.24443 pmid:26017892

    CrossRefPubMed
11. 11.↵
    1. Reis GF,
    2. Pekmezci M,
    3. Hansen HM, et al

    . CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization grades II-III) astrocytomas. J Neuropathol Exp Neurol 2015;74:442–42 doi:10.1097/NEN.0000000000000188 pmid:25853694

    CrossRefPubMed
12. 12.↵
    1. Aibaidula A,
    2. Chan AK,
    3. Shi Z, et al

    . Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol 2017;19:1327–37 doi:10.1093/neuonc/nox078 pmid:28575485

    CrossRefPubMed
13. 13.↵
    1. Park YW,
    2. Han K,
    3. Ahn SS, et al

    . Prediction of IDH1-mutation and 1p/19q-codeletion status using preoperative MR imaging phenotypes in lower grade gliomas. AJNR Am J Neuroradiol 2018;39:37–42 doi:10.3174/ajnr.A5421 pmid:29122763

    Abstract/FREE Full Text
14. 14.↵
    1. Lasocki A,
    2. Gaillard F,
    3. Gorelik A, et al

    . MRI features can predict 1p/19q status in intracranial gliomas. AJNR Am J Neuroradiol 2018;39:687–92 doi:10.3174/ajnr.A5572 pmid:29519793

    Abstract/FREE Full Text
15. 15.↵
    1. Smits M,
    2. van den Bent MJ

    . Imaging correlates of adult glioma genotypes. Radiology 2017;284:316–31 doi:10.1148/radiol.2017151930 pmid:28723281

    CrossRefPubMed
16. 16.↵
    1. Jenkinson MD,
    2. Du Plessis DG,
    3. Smith TS, et al

    . Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006;129:1884–91 doi:10.1093/brain/awl108 pmid:16670176

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Megyesi JF,
    2. Kachur E,
    3. Lee DH, et al

    . Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004;10:4303–06 doi:10.1158/1078-0432.CCR-04-0209 pmid:15240515

    Abstract/FREE Full Text
18. 18.↵
    1. Patel SH,
    2. Poisson LM,
    3. Brat DJ, et al

    . T2–FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res 2017;23:6078–85 doi:10.1158/1078-0432.CCR-17-0560 pmid:28751449

    Abstract/FREE Full Text
19. 19.↵
    1. Batchala PP,
    2. Muttikkal TJ,
    3. Donahue JH, et al

    . Neuroimaging-based classification algorithm for predicting 1p/19q-codeletion status in IDH-mutant lower grade gliomas. AJNR Am J Neuroradiol 2019;40:426–32 doi:10.3174/ajnr.A5957 pmid:30705071

    Abstract/FREE Full Text
20. 20.↵
    1. Aliotta E,
    2. Nourzadeh H,
    3. Batchala P, et al

    . Molecular subtype classification in lower-grade glioma with accelerated DTI. AJNR Am J Neuroradiol 2019;40:1458–63 doi:10.3174/ajnr.A6162 pmid:31413006

    Abstract/FREE Full Text
21. 21.↵
    Radiology Data from The Cancer Genome Atlas Low Grade Glioma [TCGA-LGG] collection. The Cancer Imaging Archive. https://www.cancerimagingarchive.net. Accessed April 11, 2019
22. 22.↵
    1. Chang EF,
    2. Smith JS,
    3. Chang SM, et al

    . Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg 2008;109:817–24 doi:10.3171/JNS/2008/109/11/0817 pmid:18976070

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Capper D,
    2. Weissert S,
    3. Balss J, et al

    . Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010;20:245–54 doi:10.1111/j.1750-3639.2009.00352.x pmid:19903171

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Capper D,
    2. Zentgraf H,
    3. Balss J, et al

    . Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009;118:599–601 doi:10.1007/s00401-009-0595-z pmid:19798509

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Ceccarelli M,
    2. Barthel FP,
    3. Malta TM, et al

    ; TCGA Research Network. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 2016;164:550–63 doi:10.1016/j.cell.2015.12.028 pmid:26824661

    CrossRefPubMed
26. 26.↵
    1. Di Carlo DT,
    2. Duffau H,
    3. Cagnazzo F, et al

    . IDH wild-type WHO grade II diffuse low-grade gliomas: a heterogeneous family with different outcomes—systematic review and meta-analysis. Neurosurg Rev 2018 Jun 26. [Epub ahead of print] doi:10.1007/s10143-018-0996-3 pmid:29943141

    CrossRefPubMed
27. 27.↵
    1. Poulen G,
    2. Goze C,
    3. Rigau V, et al

    . Huge heterogeneity in survival in a subset of adult patients with resected, wild-type isocitrate dehydrogenase status, WHO grade II astrocytomas. J Neurosurg 2018 Apr 20. [Epub ahead of print] doi:10.3171/2017.10.JNS171825 pmid:29676695

    CrossRefPubMed
28. 28.↵
    1. Wijnenga M,
    2. French PJ,
    3. Dubbink HJ, et al

    . Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma. J Neurooncol 2018;139:349–57 doi:10.1007/s11060-018-2867-8 pmid:29663171

    CrossRefPubMed
29. 29.↵
    1. Wijnenga MM,
    2. Dubbink HJ,
    3. French PJ, et al

    . Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol 2017;134:957–59 doi:10.1007/s00401-017-1781-z pmid:29052002

    CrossRefPubMed
30. 30.↵
    1. Brat DJ,
    2. Aldape K,
    3. Colman H, et al

    . cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.” Acta Neuropathol 2018;136:805–10 doi:10.1007/s00401-018-1913-0 pmid:30259105

    CrossRefPubMed
31. 31.↵
    1. Chi AS,
    2. Batchelor T,
    3. Yang D, et al

    . BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol 2013;31:e233–36 doi:10.1200/JCO.2012.46.0220 pmid:23547069

    FREE Full Text
32. 32.↵
    1. Chan AY,
    2. Zhang RQ,
    3. Aibaidula A, et al

    . BRAF mutation marks out specific subgroups of glioma. Glioma 2018;1:168 doi:10.4103/glioma.glioma_33_18

    CrossRef
33. 33.↵
    1. Aibaidula A,
    2. Chan AK,
    3. Shi Z, et al

    . Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro-Oncology 2017;19:1327–37 doi:10.1093/neuonc/nox078 pmid:28575485

    CrossRefPubMed
34. 34.↵
    1. Jafri NF,
    2. Clarke JL,
    3. Weinberg V, et al

    . Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro-Oncology 2013;15:91–96 doi:10.1093/neuonc/nos268 pmid:23095230

    CrossRefPubMed
35. 35.↵
    1. Wu CC,
    2. Jain R,
    3. Neto L, et al

    . MR imaging phenotype correlates with extent of genome-wide copy number abundance in IDH mutant gliomas. Neuroradiology 2019;61:1023–31 doi:10.1007/s00234-019-02219-8 pmid:31134296

    CrossRefPubMed
36. 36.↵
    1. Suchorska B,
    2. Schüller U,
    3. Biczok A, et al

    . Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning. Eur J Cancer 2019;107:15–27 doi:10.1016/j.ejca.2018.10.019 pmid:30529899

    CrossRefPubMed
37. 37.↵
    1. Wu C,
    2. Jain R,
    3. Radmanesh A, et al

    . Predicting genotype and survival in glioma using standard clinical MR imaging apparent diffusion coefficient images: a pilot study from the Cancer Genome Atlas. AJNR Am J Neuroradiol 2018;39:1814–20 doi:10.3174/ajnr.A5794 pmid:30190259

    Abstract/FREE Full Text
38. 38.↵
    1. Hakyemez B,
    2. Erdogan C,
    3. Ercan I, et al

    . High-grade and low-grade gliomas: differentiation by using perfusion MR imaging. Clin Radiol 2005;60:493–502 doi:10.1016/j.crad.2004.09.009 pmid:15767107

    CrossRefPubMed
39. 39.↵
    1. Komatsu K,
    2. Wanibuchi M,
    3. Mikami T, et al

    . Arterial spin labeling method as a supplemental predictor to distinguish between high- and low-grade gliomas. World Neurosurg 2018;114:e495–500 doi:10.1016/j.wneu.2018.03.015 pmid:29530684

    CrossRefPubMed
40. 40.↵
    1. Togao O,
    2. Hiwatashi A,
    3. Yamashita K, et al

    . Differentiation of high-grade and low-grade diffuse gliomas by intravoxel incoherent motion MR imaging. Neuro-Oncology 2016;18:132–41 doi:10.1093/neuonc/nov147 pmid:26243792

    CrossRefPubMed
41. 41.↵
    1. Leu K,
    2. Ott GA,
    3. Lai A, et al

    . Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II–III diffuse gliomas. J Neurooncol 2017;134:177–88 doi:10.1007/s11060-017-2506-9 pmid:28547590

    CrossRefPubMed
42. 42.↵
    1. Delgado AF,
    2. Delgado AF

    . Discrimination between glioma grades II and III using dynamic susceptibility perfusion MRI: a meta-analysis. AJNR Am J Neuroradiol 2017;38:1348–55 doi:10.3174/ajnr.A5218 pmid:28522666

    Abstract/FREE Full Text
43. 43.↵
    1. White M,
    2. Zhang Y,
    3. Kirby P, et al

    . Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol 2005;26:784–90

    Abstract/FREE Full Text
44. 44.↵
    1. Smirniotopoulos JG,
    2. Murphy FM,
    3. Rushing EJ, et al

    . Patterns of contrast enhancement in the brain and meninges. Radiographics 2007;27:525–51 doi:10.1148/rg.272065155 pmid:28522666

    CrossRefPubMedWeb of Science
45. 45.↵
    1. Young GS

    . Advanced MRI of adult brain tumors. Neurol Clin 2007;25:947–73 doi:10.1016/j.ncl.2007.07.010 pmid:17964022

    CrossRefPubMedWeb of Science
46. 46.↵
    1. Patel SH,
    2. Bansal AG,
    3. Young EB, et al

    . Extent of surgical resection in lower-grade glioma: differential impact based on molecular subtype. AJNR Am J Neuroradiol 2019;40:1149–55 doi:10.3174/ajnr.A6102 pmid:31248860

    Abstract/FREE Full Text
47. 47.↵
    1. Wijnenga MM,
    2. French PJ,
    3. Dubbink HJ, et al

    . The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol 2018;20:103–12 doi:10.1093/neuonc/nox176 pmid:29016833

    CrossRefPubMed